Cargando…

A PD-L1-Based Cancer Vaccine Elicits Antitumor Immunity in a Mouse Melanoma Model

Engagement of programmed death 1 receptor (PD-1) and its ligand PD-L1/2 induces a signal transduction pathway that inhibits the activity of tumor-infiltrating cytotoxic T lymphocytes and promotes tumor growth and metastasis. Antibodies blocking PD-1 or PD-L1 can restore antitumor T cell responses an...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lin, Zhibing, Zhang, Yan, Cai, Huaman, Zhou, Fuqiang, Gao, Hongjun, Deng, Li, Li, Rongxiu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Gene & Cell Therapy 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6667823/ https://www.ncbi.nlm.nih.gov/pubmed/31384666 http://dx.doi.org/10.1016/j.omto.2019.06.002

Ejemplares similares

The Immunogenicity and Anti-tumor Efficacy of a Rationally Designed Neoantigen Vaccine for B16F10 Mouse Melanoma
por: Zhang, Yan, et al.
Publicado: (2019)

Recombinant Costimulatory Fusion Proteins as Functional Immunomodulators Enhance Antitumor Activity in Murine B16F10 Melanoma
por: Cai, Huaman, et al.
Publicado: (2020)

Recombinant KRAS G12D Protein Vaccines Elicit Significant Anti-Tumor Effects in Mouse CT26 Tumor Models
por: Wan, Yuhua, et al.
Publicado: (2020)

Abrine Elicits Liver Carcinoma Immunity and Enhances Antitumor Efficacy of Immune Checkpoint Blockade by Modulating PD-L1 Signaling
por: Zhang, Shaowu
Publicado: (2022)

An mRNA vaccine elicits STING-dependent antitumor immune responses
por: Chen, Zhe, et al.
Publicado: (2023)

WNK3 inhibition elicits antitumor immunity by suppressing PD-L1 expression on tumor cells and activating T-cell function
por: Yoon, Hyun Ju, et al.
Publicado: (2022)

Colocalized targeting of TGF-β and PD-L1 by bintrafusp alfa elicits distinct antitumor responses
por: Lan, Yan, et al.
Publicado: (2022)

Vaccination with CD47 deficient tumor cells elicits an antitumor immune response in mice
por: Li, Yang, et al.
Publicado: (2020)

Function of PD-L1 in antitumor immunity of glioma cells
por: Lou, Yongli, et al.
Publicado: (2017)

IM-6 HVJ-E containing PD-L1 siRNA inhibits immunosuppressive activities and elicits antitumor immune responses in glioma
por: Sugii, Narushi, et al.
Publicado: (2021)

Tumor-associated neutrophils suppress antitumor immunity of NK cells through the PD-L1/PD-1 axis
por: Sun, Rui, et al.
Publicado: (2020)

TRAPPC4 regulates the intracellular trafficking of PD-L1 and antitumor immunity
por: Ren, Yimeng, et al.
Publicado: (2021)

Epigenetics Regulates Antitumor Immunity in Melanoma
por: Chen, Yuhan, et al.
Publicado: (2022)

Canagliflozin primes antitumor immunity by triggering PD-L1 degradation in endocytic recycling
por: Ding, Ling, et al.
Publicado: (2023)

Tumor-repopulating cell-derived microparticles elicit cascade amplification of chemotherapy-induced antitumor immunity to boost anti-PD-1 therapy
por: Bie, Nana, et al.
Publicado: (2023)

PD-1/PD-L1 Blockade: Have We Found the Key to Unleash the Antitumor Immune Response?
por: Xu-Monette, Zijun Y., et al.
Publicado: (2017)

Diosgenin promotes antitumor immunity and PD-1 antibody efficacy against melanoma by regulating intestinal microbiota
por: Dong, Mengxue, et al.
Publicado: (2018)

Cripto-1 vaccination elicits protective immunity against metastatic melanoma
por: Ligtenberg, M. A., et al.
Publicado: (2016)

L-5-hydroxytryptophan promotes antitumor immunity by inhibiting PD-L1 inducible expression
por: Huang, Jing, et al.
Publicado: (2022)

In situ vaccination with cowpea mosaic virus elicits systemic antitumor immunity and potentiates immune checkpoint blockade
por: Mao, Chenkai, et al.
Publicado: (2022)

AURKA inhibitor-induced PD-L1 upregulation impairs antitumor immune responses
por: Meng, Bi, et al.
Publicado: (2023)

Superagonist IL-15-Armed Oncolytic Virus Elicits Potent Antitumor Immunity and Therapy That Are Enhanced with PD-1 Blockade
por: Kowalsky, Stacy J., et al.
Publicado: (2018)

ZnO-based multifunctional nanocomposites to inhibit progression and metastasis of melanoma by eliciting antitumor immunity via immunogenic cell death
por: Zhang, Yamin, et al.
Publicado: (2020)

A Novel Humanized PD-1/PD-L1 Mouse Model Permits Direct Comparison of Antitumor Immunity Generated by Food and Drug Administration–Approved PD-1 and PD-L1 Inhibitors
por: Barham, Whitney, et al.
Publicado: (2023)

Study and analysis of antitumor resistance mechanism of PD1/PD‐L1 immune checkpoint blocker
por: Wang, Zhengyi, et al.
Publicado: (2020)

Drug Repurposing to Enhance Antitumor Response to PD-1/PD-L1 Immune Checkpoint Inhibitors
por: Thuru, Xavier, et al.
Publicado: (2022)

SOCS1 favors the epithelial-mesenchymal transition in melanoma, promotes tumor progression and prevents antitumor immunity by PD-L1 expression
por: Berzaghi, R., et al.
Publicado: (2017)

Dual activity of PD-L1 targeted Doxorubicin immunoliposomes promoted an enhanced efficacy of the antitumor immune response in melanoma murine model
por: Merino, María, et al.
Publicado: (2021)

The cryo-thermal therapy eradicated melanoma in mice by eliciting CD4(+) T-cell-mediated antitumor memory immune response
por: He, Kun, et al.
Publicado: (2017)

Uncarboxylated Osteocalcin Induces Antitumor Immunity against Mouse Melanoma Cell Growth
por: Hayashi, Yoshikazu, et al.
Publicado: (2017)

CXCL13 expression in mouse 4T1 breast cancer microenvironment elicits antitumor immune response by regulating immune cell infiltration
por: Ma, Qizhi, et al.
Publicado: (2021)

Apigenin suppresses PD-L1 expression in melanoma and host dendritic cells to elicit synergistic therapeutic effects
por: Xu, Lu, et al.
Publicado: (2018)

Therapeutic depletion of CCR8(+) tumor-infiltrating regulatory T cells elicits antitumor immunity and synergizes with anti-PD-1 therapy
por: Van Damme, Helena, et al.
Publicado: (2021)

Multifunctional magnetic nanoparticles elicit anti-tumor immunity in a mouse melanoma model
por: Lafuente-Gómez, Nuria, et al.
Publicado: (2023)

Irreversible electroporation combined with chemotherapy and PD-1/PD-L1 blockade enhanced antitumor immunity for locally advanced pancreatic cancer
por: Ma, Yangyang, et al.
Publicado: (2023)

Peptide vaccination directed against IDO1-expressing immune cells elicits CD8(+) and CD4(+) T-cell-mediated antitumor immunity and enhanced anti-PD1 responses
por: Dey, Souvik, et al.
Publicado: (2020)

Erratum: SOCS1 favors the epithelial-mesenchymal transition in melanoma, promotes tumor progression and prevents antitumor immunity by PD-L1 expression
por: Berzaghi, R., et al.
Publicado: (2017)

Pirfenidone facilitates immune infiltration and enhances the antitumor efficacy of PD-L1 blockade in mice
por: Qin, Wan, et al.
Publicado: (2020)

Alarmin-painted exosomes elicit persistent antitumor immunity in large established tumors in mice
por: Zuo, Bingfeng, et al.
Publicado: (2020)

Resveratrol targets PD-L1 glycosylation and dimerization to enhance antitumor T-cell immunity
por: Verdura, Sara, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_dttpdgtsq8e384b5vqsn07h13b